VC
TARS icon

Vivo Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Vivo Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-565,550
Closed -$15.4M – 44
2024
Q2 		$15.4M Hold
565,550
– – 1.42% 16
2024
Q1 		$20.6M Sell
565,550
-1,218,456
-68% -$35.8M 1.62% 16
2023
Q4 		$36.1M Sell
1,784,006
-478,194
-21% -$7.98M 2.96% 10
2023
Q3 		$40.2M Hold
2,262,200
– – 4.4% 6
2023
Q2 		$40.9M Hold
2,262,200
– – 2.82% 7
2023
Q1 		$28.4M Hold
2,262,200
– – 1.97% 9
2022
Q4 		$33.2M Hold
2,262,200
– – 3.82% 10
2022
Q3 		$38.7M Sell
2,262,200
-50,168
-2% -$797K 4.28% 6
2022
Q2 		$33.8M Sell
2,312,368
-674,963
-23% -$10.1M 3.39% 7
2022
Q1 		$50.2M Hold
2,987,331
– – 3.46% 9
2021
Q4 		$67.2M Hold
2,987,331
– – 4.05% 6
2021
Q3 		$64.4M Hold
2,987,331
– – 2.89% 9
2021
Q2 		$86.6M Sell
2,987,331
-257,704
-8% -$8.05M 3.75% 8
2021
Q1 		$105M Hold
3,245,035
– – 3.68% 9
2020
Q4 		$134M Buy
+3,245,035
New +$92.4M 5.99% 4

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital's TARS Position: Q3 2024 in Review

Vivo Capital sold out of Tarsus Pharmaceuticals (TARS) in Q3 2024, closing a stake of 565,550 shares — an estimated $15.4M sold.

Vivo Capital first reported a position in TARS in Q4 2020 and held it in 15 quarters. The position peaked at $134M in Q4 2020. 162 funds tracked by Wall St. Rank hold TARS as of Q3 2024.

  • Vivo Capital reported no remaining Tarsus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Vivo Capital sold 565,550 Tarsus Pharmaceuticals shares in Q3 2024, an estimated $15.4M.
  • Vivo Capital first reported a position in Tarsus Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Vivo Capital's Tarsus Pharmaceuticals position peaked at $134M in Q4 2020.
  • 162 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2024.

Based on Vivo Capital's 13F filing for Q3 2024, filed 13 Nov 2024.